Cost-effectiveness analysis of cisplatin-based chemoradiation to treat patients with unresectable, nonmetastatic head and neck cancer in Brazil

Head and Neck

Volumn 33, Issue 8, 2011, Pages 1199-1205

  Brentani, Alexandra ^a   De Castro Jr , Gilberto ^a   Federico, Miriam H ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

chemoradiation; cisplatin; cost effectiveness; economic analysis; head and neck cancer

Indexed keywords

CISPLATIN;

ADVANCED CANCER; AGED; ARTICLE; CANCER PATIENT; CHEMORADIOTHERAPY; CLINICAL ARTICLE; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DISEASE COURSE; FEBRILE NEUTROPENIA; FEMALE; HEAD AND NECK CANCER; HUMAN; MALE; MEDICAL RECORD; MUCOSA INFLAMMATION; NATIONAL HEALTH ORGANIZATION; NAUSEA; NEUTROPENIA; PAIN; PRIORITY JOURNAL; RADIATION DERMATITIS; REIMBURSEMENT; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; UNITED STATES;

EID: 79960388068     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21601     Document Type: Article

References (23)

1. Ministério da Saúde-Sistema de informaçÃμes de mortalidade DATASUS. Brasília, 2008.
2. Parkin DM, Bray F, Ferlay J, Pisani P,. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94: 153-156. (Pubitemid 32911406)
3. Ministério da Saúde, Instituto Nacional de Câncer-INCA. Brasília, 2008.
4. Cooper JS, Pajak TF, Forastiere AA, et al. Prospective concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. New Engl J Med 2004; 350: 1937-1944.
5. Kowalski LP, Bagietto R,;, Lara JR, Santos RL, Silva JF Jr, Magrin J,. Prognostic significance of the distribution of neck node metastasis from oral carcinoma. Head Neck 2000; 22: 207-214. (Pubitemid 30215315)
6. Brockstein B, Vokes EE,. Concurrent chemotherapy for head and neck cancer. Semin Oncol 2004; 31: 786-793. (Pubitemid 39602684)
7. Ludwig H,. Optimum cancer care-an unaffordable goal? Lancet Oncol 2004; 5: 529-530. (Pubitemid 39194040)
8. Bourhis J, Amand C, Pignon JP,; on behalf of the MACH-NC Collaborative Group. Update of MACH-NC (Meta-Analysis of Chemotherapy in Head & Neck Cancer) database focused on concomitant chemoradiotherapy. J Clin Oncol 2004; 22: 5505.
9. Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003; 21: 92-98.
10. Rosenthal DI, Ang KK,. Altered radiation therapy fractionation, chemoradiation, and patient selection for the treatment of head and neck squamous carcinoma. Semin Radiat Oncol 2004; 14: 153-166. (Pubitemid 38586109)
11. Soto J,. Health economic evaluations using decision analytic modeling. Principles and practices-utilization of a checklist to their development and appraisal. Int J Technol Assess Health Care 2002; 18: 94-111. (Pubitemid 34408532)
12. Brown J,. Economic evaluation of cancer treatments: a review of the Methods: Clin Oncol (R Coll Radiol) 1999; 11: 78-83. (Pubitemid 29259568)
13. Drummond MB, Stoddart GL,. Methods: for the economic evaluation of health care programs, 2nd ed. London: Oxford Medical Publications; 1997.
14. Earle CC, Coyle D, Evans WK,. Cost-effectiveness analysis in oncology. Ann Oncol 1998; 9: 475-482. (Pubitemid 28270633)
15. Neymark N,. Techniques for health economic analyses in oncology: part 1. Crit Rev Oncol/Hematol 1998; 30: 1-11.
16. Duru G, Auray JP, Béresniak A, Lamure M, Paine A, Nicoloyannis N,. Limitations of the Methods: used for calculating quality-adjusted life-year values. Pharmacoeconomics 2002; 20: 463-473. (Pubitemid 34804175)
17. Neymark N,. Techniques for health economics analyses in oncology: part 2. Crit Rev Oncol/Hematol 1999; 30: 13-24. (Pubitemid 29294708)
18. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Eng J Med 2004; 350: 1945-1952. (Pubitemid 38580197)
19. Brizel DM, Albers ME, Fisher SR, et al. Hyperfractionated irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998; 338: 1798-1804. (Pubitemid 28277960)
20. Uyl-de Groot CA,. Economic evaluation of cancer therapies: more and better studies will lead to better choices in cancer care. Eur J Cancer 2006; 42: 2862-2866.
21. Lee M, Aristides M, Maniadakis N, McKendrick J, Botwood N, Stephenson D,. Economic evaluation of gemcitabine alone and in combination with cisplatin in treatment of nonsmall cell lung cancer. Pharmacoeconomics 2002; 20: 325-337. (Pubitemid 34569366)
22. Ministério da Saúde. Secretaria-Executiva. Área de Economia da Saúde e Desenvolvimento. Avaliação econômica em saúde: desafios para gestão no Sistema Único de Saúde/Ministério da Saúde. Ministério da Saúde, 2008.
23. World Health Organization (WHO). WHO Guidelines standardization of economic evaluation of immunization programmes, 2008. pp. 65-68.